PMID- 27075916
OWN - NLM
STAT- MEDLINE
DCOM- 20161223
LR  - 20220331
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 156
IP  - 3
DP  - 2016 Apr
TI  - MxA expression is associated with tumor-infiltrating lymphocytes and is a 
      prognostic factor in triple-negative breast cancer.
PG  - 597-606
LID - 10.1007/s10549-016-3786-z [doi]
AB  - Interferons (IFNs) play an important role in tumor-immune system interactions. As 
      one of the main mediators of IFNs, myxovirus resistance A (MxA) is upregulated in 
      various cancers. However, the exact role of MxA in breast cancer is not fully 
      understood. As part of the immune response to tumors, tumor-infiltrating 
      lymphocytes (TILs) have prognostic significance in breast cancer. The aim of our 
      present study was to examine the relationship between MxA and immune system 
      components, including the amount of TILs and human leukocyte antigen (HLA) 
      expression, in breast cancer. TILs, MxA expression, HLA intensity, and 
      clinicopathological factors were retrospectively analyzed in 688 patients with 
      primary breast cancer between 1993 and 1998 and in 705 patients with 
      triple-negative breast cancer (TNBC) between 2004 and 2011. MxA expression was 
      higher in TNBC tumors than in other subtypes. High MxA levels were associated 
      with a higher histologic grade, abundant TILs, and stronger HLA-ABC expression in 
      both the TNBC subtype within the consecutive breast cancer cohort and the 
      validation TNBC cohort. MxA expression showed a significant positive correlation 
      with TILs, the number of CD8(+) cells, and the number of CD69(+) cells in the 
      validation TNBC cohort. High MxA levels and abundant TILs were found to be 
      independent prognostic factors for disease-free survival in patients with TNBC. 
      These results indicate that MxA expression is closely related to TILs in TNBC 
      and, along with TILs, provides prognostic information after chemotherapy in 
      patients with TNBC.
FAU - Kim, Young-Ae
AU  - Kim YA
AD  - Department of Pathology, Asan Medical Center, University of Ulsan College of 
      Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Republic of Korea.
FAU - Lee, Hee Jin
AU  - Lee HJ
AD  - Department of Pathology, Asan Medical Center, University of Ulsan College of 
      Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Republic of Korea.
FAU - Heo, Sun-Hee
AU  - Heo SH
AD  - Department of Pathology, Asan Medical Center, University of Ulsan College of 
      Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Republic of Korea.
FAU - Park, Hye Seon
AU  - Park HS
AD  - Department of Pathology, Asan Medical Center, University of Ulsan College of 
      Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Republic of Korea.
FAU - Park, Suk Young
AU  - Park SY
AD  - Department of Pathology, Asan Medical Center, University of Ulsan College of 
      Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Republic of Korea.
FAU - Bang, WonSeon
AU  - Bang W
AD  - Department of Pathology, Asan Medical Center, University of Ulsan College of 
      Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Republic of Korea.
FAU - Song, In Hye
AU  - Song IH
AD  - Department of Pathology, Asan Medical Center, University of Ulsan College of 
      Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Republic of Korea.
FAU - Park, In Ah
AU  - Park IA
AD  - Department of Pathology, Asan Medical Center, University of Ulsan College of 
      Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Republic of Korea.
FAU - Gong, Gyungyub
AU  - Gong G
AD  - Department of Pathology, Asan Medical Center, University of Ulsan College of 
      Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Republic of Korea. 
      gygong@amc.seoul.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160413
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, T-Lymphocyte)
RN  - 0 (CD69 antigen)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Lectins, C-Type)
RN  - 0 (MX1 protein, human)
RN  - 0 (Myxovirus Resistance Proteins)
SB  - IM
MH  - Antigens, CD/metabolism
MH  - Antigens, Differentiation, T-Lymphocyte/metabolism
MH  - CD8-Positive T-Lymphocytes/metabolism
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Histocompatibility Antigens Class I/metabolism
MH  - Humans
MH  - Lectins, C-Type/metabolism
MH  - Lymphocytes, Tumor-Infiltrating/metabolism/*pathology
MH  - Myxovirus Resistance Proteins/*metabolism
MH  - Prognosis
MH  - Retrospective Studies
MH  - Tissue Array Analysis/*methods
MH  - Triple Negative Breast Neoplasms/immunology/metabolism/*pathology
MH  - *Up-Regulation
OTO - NOTNLM
OT  - Breast carcinoma
OT  - Human leukocyte antigen
OT  - Interferon
OT  - Myxovirus resistance A
OT  - Tumor-infiltrating lymphocytes
EDAT- 2016/04/15 06:00
MHDA- 2016/12/24 06:00
CRDT- 2016/04/15 06:00
PHST- 2016/01/06 00:00 [received]
PHST- 2016/04/05 00:00 [accepted]
PHST- 2016/04/15 06:00 [entrez]
PHST- 2016/04/15 06:00 [pubmed]
PHST- 2016/12/24 06:00 [medline]
AID - 10.1007/s10549-016-3786-z [pii]
AID - 10.1007/s10549-016-3786-z [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2016 Apr;156(3):597-606. doi: 10.1007/s10549-016-3786-z. 
      Epub 2016 Apr 13.